| Literature DB >> 26711748 |
Dongming Zhao1, Satoshi Fukuyama1, Yuko Sakai-Tagawa2, Emi Takashita3, Jason E Shoemaker1, Yoshihiro Kawaoka4.
Abstract
New strategies to develop novel broad-spectrum antiviral drugs against influenza virus infections are needed due to the emergence of antigenic variants and drug-resistant viruses. Here, we evaluated C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase (HAT), as an anti-influenza virus agent in vitro and in vivo and explored how C646 affects the viral life cycle and host response. Our studies highlight the value of targeting HAT activity for anti-influenza drug development.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26711748 PMCID: PMC4776003 DOI: 10.1128/AAC.02055-15
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191